Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Katsuyuki Hori"'
Publikováno v:
Japanese Journal of Infection Prevention and Control. 36:111-116
Autor:
Katsuyuki Hori, Kenji Kiyohara, Haruo Maruyama, Nobuhiro Yasuoka, Yoshiki Matsuoka, Sachiko Otsuka, Ken Kubota, Kenji Tanaka, Shohei Katsuno
Publikováno v:
Japanese Journal of Infection Prevention and Control. 29:361-368
Autor:
Nobuhiro Yasuoka, Kenji Tanaka, Katsuyuki Hori, Kenji Kiyohara, Haruo Maruyama, Shohei Katsuno, Yoshiki Matsuoka, Ken Kubota
Publikováno v:
Japanese Journal of Infection Prevention and Control. 28:361-366
Autor:
Kenji KIYOHARA, Ken KUBOTA, Haruo MARUYAMA, Shohei KATSUNO, Kenji TANAKA, Chika TOBUSAWA, Nobuhiro YASUOKA, Katsuyuki HORI
Publikováno v:
Japanese Journal of Environmental Infections. 26:105-116
Autor:
Tsuyoshi Minematsu, Katsuyuki Hori, Takashi Usui, Jiuhong Zha, Selina Moy, Jennifer Lee, Koji Ishibashi, Hidetaka Kamimura, Donna Kowalski
Publikováno v:
Drug Metabolism and Disposition. 38:249-259
We investigated the inhibitory effects of FK1706, a novel non-immunosuppressive immunophilin ligand, on CYP3A4/5 in in vitro and in vivo settings. First, the inhibitory effects of FK1706 (preincubation dependency, inactivation rate estimation, and re
Autor:
Yasuro Kawaguchi, Katsuyuki Hori, Hirotoshi Masuda, Sekio Nagayama, Yoshio Esumi, Toshiyuki Mashiko
Publikováno v:
Drug Metabolism and Pharmacokinetics. 12:355-386
S-1, a new oral anti-cancer drug, is composed of tegafur (FT), gimestat (CDHP) and potassium otastat (Oxo) in a molar ratio of 1 : 0.4 : 1. FT which is masked compound of 5-fluorouracil (5-FU) plays a role as an effector. Both CDHP and Oxo which do n
Autor:
Toshiyuki Mashiko, Yasuro Kawaguchi, Hirotoshi Masuda, Katsuyuki Hori, Sekio Nagayama, Yoshio Esumi
Publikováno v:
Drug Metabolism and Pharmacokinetics. 12:332-354
S-1, a new oral anti-cancer drug, is composed of tegafur (FT), gimestat (CDHP) and potassium otastat (Oxo) in a molar ratio of 1 : 0.4 : 1. FT which is masked compound of 5-fluorouracil (5-FU) plays a role as an effector. Both CDHP and Oxo which do n
Autor:
Katsuyuki Hori, Yasuro Kawaguchi, Hirotoshi Masuda, Kisako Toko, Toshiyuki Mashiko, Sekio Nagayama, Yoshio Esumi
Publikováno v:
Drug Metabolism and Pharmacokinetics. 12:301-321
S-1, a new oral anti-cancer drug, is composed of tegafur(FT), gimestat(CDHP) and potassium otastat(Oxo) in a molar ratio of 1 : 0.4 : 1. FT which is masked compound of 5-fluorouracil (5-FU) plays a role as an effector. Both CDHP and Oxo which do not
Autor:
Kisako Toko, Yasuro Kawaguchi, Kazumasa Ikeda, Toshiyuki Mashiko, Sekio Nagayama, Yoshio Esumi, Hirotoshi Masuda, Katsuyuki Hori
Publikováno v:
Drug Metabolism and Pharmacokinetics. 12:289-300
S-1, a new oral anti-cancer drug, is composed of tegafur(FT), gimestat(CDHP) and potassium otastat(Oxo) in a molar ratio of 1 : 0.4 : 1. FT which is masked compound of 5 fluorouracil (5-FU) plays a role as an effector. Both CDHP and Oxo which do not
Autor:
Kisako Toko, Kazuta Oguri, Yasuro Kawaguchi, Hirotoshi Masuda, Katsuyuki Hori, Sekio Nagayama, Yoshio Esumi, Toshiyuki Mashiko
Publikováno v:
Drug Metabolism and Pharmacokinetics. 12:322-331